Bunnapradist Suphamai, Chung Philip, Peng Alice, Hong Andy, Chung Peter, Lee Brian, Fukami Sumina, Takemoto Steven K, Singh Ajay K
Transplantation. 2006 Sep 15;82(5):612-8. doi: 10.1097/01.tp.0000235740.56573.c6.
Prior analyses of transplant outcomes in lupus transplant recipients have not consisted of multivariate analyses in the modern immunosuppressive era. Here, we compared patient and graft outcomes in lupus and non-lupus recipients transplanted between 1996 to 2000 using the United Network of Organ Sharing/Organ Procurement Transplant Network database. We evaluated the impact of recipient and donor demographic factors, time on dialysis and the initial immunosuppression regimen on rejection rates and transplant outcomes. Univariate analysis showed similar graft but better patient survival rates for primary lupus and non-lupus transplant recipients (5-year patient survival rates for lupus cohort 85.2% for deceased donor transplants and 92.1% for living donor transplants as opposed to 82.1% and 89.8% respectively for the non-lupus cohort; P=0.05 and 0.03) but similar patient survival rates for deceased donor retransplant patients. After controlling for confounding factors, no differences in patient or graft survival were seen between the two groups. No difference in acute rejection rates were observed in deceased donor transplants, but there was a small but significant increase in the risk of acute rejection in living donor lupus transplant recipients (hazard ratio=1.19, P=0.05). Risk of graft failure was lower for deceased donor recipients receiving MMF (five-year graft loss rate=29.6% for MMF vs. 40.2% for those not receiving MMF, P<0.0001), but no differences were seen among living donor recipients. Outcomes were similar regardless of type of calcineurin inhibitor, induction therapy, and time on dialysis. We conclude that lupus transplant recipients have outcomes generally equivalent to non-lupus transplant recipients.
此前对狼疮移植受者移植结局的分析未包括现代免疫抑制时代的多变量分析。在此,我们使用器官共享联合网络/器官获取移植网络数据库,比较了1996年至2000年间进行移植的狼疮和非狼疮受者的患者及移植物结局。我们评估了受者和供者的人口统计学因素、透析时间以及初始免疫抑制方案对排斥率和移植结局的影响。单变量分析显示,原发性狼疮和非狼疮移植受者的移植物情况相似,但患者生存率更高(狼疮队列的5年患者生存率, deceased donor移植为85.2%, living donor移植为92.1%,而非狼疮队列分别为82.1%和89.8%;P = 0.05和0.03),但 deceased donor再次移植患者的患者生存率相似。在控制混杂因素后,两组之间的患者或移植物生存率未见差异。在 deceased donor移植中,急性排斥率未见差异,但 living donor狼疮移植受者的急性排斥风险有小幅但显著增加(风险比 = 1.19,P = 0.05)。接受霉酚酸酯的 deceased donor受者的移植物失败风险较低(霉酚酸酯组的5年移植物丢失率为29.6%,未接受霉酚酸酯组为40.2%,P < 0.0001),但 living donor受者之间未见差异。无论使用何种钙调神经磷酸酶抑制剂、诱导治疗以及透析时间,结局均相似。我们得出结论,狼疮移植受者的结局总体上与非狼疮移植受者相当。